A Clinical Trial to Evaluate the Effect of Neoadjuvant MK-3475 (Pembrolizumab) Therapy on Intratumoral Immune Infiltrates in Renal Cell Cancer (RCC) Patients Undergoing Surgical Resection
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 14 May 2018 Planned End Date changed from 21 Jun 2021 to 2 Oct 2019.